April 4, 2022

CARB-X Awards Clarametyx Biosciences $3.89 Million in Additional Option Funding to Accelerate Anti-biofilm Technology for Life-threatening Bacterial Infections

Supplemental award extends CARB-X collaboration as the Company advances toward first-in-human clinical trials in 2022

COLUMBUS, Ohio – April 4, 2022 – Clarametyx Biosciences Inc. (“Clarametyx”), a preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter serious infections associated with biofilms, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to accelerating antibacterial research and development, has awarded the company an additional $3.89 million in option funding. The grant is directed toward accelerated development of CMTX-101, a novel anti-biofilm therapy with a first targeted indication for moderate-to-severe pneumonia.

This supplemental option builds upon the previous funding awards received in 2020 and 2021, and is oriented toward IND-enabling activities such as a GLP toxicity study and Phase 1 material production. Based on the terms of the agreement, Clarametyx will be eligible for one further funding option supporting a first-in-human clinical trial, dependent on achievement of certain developmental milestones and that the product remains a competitive addition to the field.

“Advancing to the next option of our agreement with CARB-X helps us further accelerate our efforts toward initiating our first-in-human clinical trials with CMTX-101 later this year,” said David Richards, Chief Executive Officer. “We appreciate the continued support by experts in our field, which reinforces the significant potential of this innovative technology to broadly address challenging bacterial infections.”

Clarametyx’s technology continues to generate momentum and awareness as an important complementary approach to antibiotic strategies to effectively resolve challenging biofilm-related infections. The Company’s platform is designed to precisely remove a universal, pathogen-agnostic target within the biofilm matrix, rapidly and effectively collapsing the protective shield and rendering the bacteria vulnerable to immune and antibiotic attack.

Acknowledgement and disclaimer

Research reported in this news release is supported by CARB-X. CARB-X’s funding for this project is sponsored by the Cooperative Agreement Number IDSEP160030 from ASPR/BARDA and by awards from the Wellcome Trust and Germany’s Federal Ministry of Education and Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders.

About CARB-X

CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership dedicated to supporting early development antibacterial R&D to address the rising threat of drug-resistant bacteria. CARB-X is led by Boston University and funding is provided by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the US Department of Health and Human Services; the Wellcome Trust, a global charity based in the UK working to improve health globally; Germany’s Federal Ministry of Education and Research (BMBF); the UK Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) funded by the UK Government Department of Health and Social Care (DHSC); the Bill & Melinda Gates Foundation, and with in-kind support from National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH) within the US Department of Health and Human Services. CARB-X is investing up to US$480 million from 2016-2022 to support innovative therapeutics, preventatives, and rapid diagnostics. CARB-X funds only projects that target drug-resistant bacteria highlighted on the CDC’s Antibiotic Resistant Threats list, or the Priority Bacterial Pathogens list published by the WHO, with a priority on those pathogens deemed Serious or Urgent on the CDC list or Critical or High on the WHO list. CARB-X is headquartered at Boston University School of Law. https://carb-x.org/. Follow us on Twitter @CARB_X.

About Clarametyx Biosciences

Clarametyx Biosciences is combating the formidable challenge of persistent and recalcitrant infections through an innovative technology platform targeting the biofilm—a protective layer around bacteria—to enable a more effective immune response or antibiotic intervention. The Columbus, Ohio-based company is building a dynamic pipeline of immune-enabling therapies and vaccines for life-threatening bacterial infections associated with biofilms. Its lead candidate, CMTX-101, is a humanized monoclonal antibody in preclinical development for hospital-acquired pneumonia. For more information, visit us on the web or on LinkedIn.

 Media Contact:

Kellie Hotz
khotz@clarametyx.com

# # #

Close

Clarametyx Expanded Access Policy

Clarametyx Biosciences is a clinical stage biopharmaceutical company committed to developing novel immune-enabling therapies for serious or difficult-to-treat respiratory diseases.

“Expanded access” refers to use of an investigational drug outside of a clinical trial, where the use of the drug is for treatment, rather than gathering data in support of a marketing application.

The main goal of ongoing clinical trials for our investigational agent, CMTX-101, is to gain information about the drug’s safety and efficacy to submit an application to Health Authorities in support of approval to market CMTX-101. For this reason, Clarametyx believes that direct enrollment in a clinical trial is the preferred route of access to a drug, for which we are continuing to develop data on safety, efficacy and tolerability. We believe expanded access outside of a clinical trial may interfere with the conduct of ongoing trials and may disrupt the progress of our development programs, which could potentially delay access to other patients in need.

For this reason, Clarametyx is not making its investigational drugs available on an expanded access basis at the present time. We plan to re-evaluate this policy in the future as additional information becomes available from ongoing clinical trials.

If you have any questions about this policy or would like information about how to participate in our clinical studies, please contact us at info@clarametyx.com. More information on our ongoing clinical trial is available at ClinicalTrials.gov (http://www.clinicaltrials.gov, NCT06159725).

As authorized by the 21st Century Cures Act, Clarametyx may revise this expanded access policy at any time.